We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Daiichi Sankyo has been hit with mixed news this week regarding its experimental therapy mirogabalin. The drug posted trial success in treating patients with post-herpetic neuralgia by hitting its primary endpoint, yet failed to hit its target in a trial